Sherpa Healthcare Partners

Sherpa Healthcare Partners (the “Sherpa”) is an innovation-driven, value-oriented, specialized healthcare investor focusing on early- and growth-stage equity investments primarily in Greater China, as well as selectively in the U.S. and other jurisdictions. The “Sherpa” name is inspired by the Sherpa people, the mountain guides in the extreme altitudes of Mount Everest. Sherpas are renowned for their Wisdom, Expertise, Bravery, and Tenacity.

Who we are

The core investment and management team of Sherpa (the “Team”) has worked together for over 13 years through at least six fund cycles , sharing the same values, mutual trust, and complementary capabilities. Each key member of the Team possesses over 10 years of investment and/or operational management experience, and Sherpa believes the Team is equipped with deep insights and strong connections within the healthcare industry.

Sherpa believes the Team has been widely recognized for its exceptional professionalism, deep expertise, and strong investment performance among the healthcare enterprise and investment communities. As of September 30, 2024, the Team had managed over US$1.9 billion with 160 portfolio companies since 2011 , focusing primarily on early- and growth-stage investments across all major healthcare subsectors including biotech/pharma, MedTech, diagnostics, healthcare services.

Sherpa Invests in High Flying Companies in Each Sector

Our portfolio
Go Icon
We/invest / in/the/future/of/healthcare
and/life-science/innovation
Team
Our team
Go Icon
Our team
Go Icon

Mission of Sherpa Healthcare Partners :

Empowering Healthcare Entrepreneurs to Ascend to New Heights

  • Former MD of Legend Capital (2004-2017), took the initiative to set up and manage the dedicated healthcare team & healthcare fund of Legend Capital (2010-2017)
  • Focusing on investments in MedTech and Medical Services
  • Previous investments including: Reach Surgical (M&A), Berry Genomics (SZSE: 000710), Vazyme (SHE:688105), Heng-tai (SZSE: 301370), Kangda Med (M&A), Urotronic (M&A), Wuhan Asia Heart Hospital
  • EMBA, CKGSB; ME, Tsinghua University; BS, Wuhan University
Xiangyu Ouyang
Managing Partner
  • Former MD of Legend Capital, co-led its healthcare investment team
  • Focusing on investments in Pharma/Biotech, Diagnostics/MedTech, Medical Services
  • Previous investments including: Berry Genomics (SZSE: 000710), Innovent (HKE: 01801), BioNano (NASDAQ: BNGO), Axonics (NASDAQ: AXNX), New Horizon (HKE: 06606), Singular (NASDAQ: OMIC), Cytek (NASDAQ: CTKB), Aohua (SHE: 688212), R&G Pharma (SZSE: 301333), Kelun Biotech (HKE: 06990), Avida (M&A), NanoVision, Belief Bio, Hui Gene, Singleron, Leto Labs, Memoray, BlissBio, Bota, and etc.
  • Ph.D, UC Berkeley; MBA, Yale University; BS, USTC
Daqing (Darren) Cai
Managing Partner
  • Former Director of Legend Capital, IC member for LC healthcare fund
  • Focusing on investments in Pharma/Biotech, Medtech and Medical Services
  • Previous investments including: Harbour BioMed (HKEX: 02142), Insight Lifetech, Lifeshield, Epimab, Visen Pharma, Zion, Kechow, Bellen, Immuno China, Belief Biomed, Huahui, etc.
  • MS & BS, Peking University
Cheng Xing
Managing Partner